ArticleGene therapy2005
Evaluation of tumor-specific promoter activities in melanoma.
Article in Gene therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 53 citations in OpenAlex.
- Self-sufficient killing of malignant tumors by an engineered cancer-selective gene circuit.Cell reports. Medicine · 2026Article
- Development of a carrier system containing hyaluronic acid and protamine for siRNA delivery in the treatment of melanoma.Investigational new drugs · 2021Article
- A Multifaceted Approach to Optimizing AAV Delivery to the Brain for the Treatment of Neurodegenerative Diseases.Frontiers in neuroscience · 2021Article
- Analysis of endogenous and exogenous tumor upregulated promoter expression in canine tumors.PloS one · 2020Article
- A novel approach for assessment of prostate cancer aggressiveness using survivin-driven tumour-activatable minicircles.Gene therapy · 2019Article
- Cyanidin-3-o-Glucoside Pharmacologically Inhibits Tumorigenesis via Estrogen Receptor β in Melanoma Mice.Frontiers in oncology · 2019Article
- High promoter activity of cytokeratin-19 gene in cholangiocarcinoma.Molecular and clinical oncology · 2018Article
- Cancer terminator viruses (CTV): A better solution for viral-based therapy of cancer.Journal of cellular physiology · 2018Review
- Review
- Seek and destroy: targeted adeno-associated viruses for gene delivery to hepatocellular carcinoma.Drug delivery · 2017Review
- Targeting Melanoma with Cancer-Killing Viruses.The open virology journal · 2017Article
- Yin Yang 1 (YY1): Regulation of Survivin and Its Role In Invasion and Metastasis.Critical reviews in oncogenesis · 2017Review
- Expression of HIF-1α ODD domain fused canine caspase 3 by EGFR promoter-driven adenovirus vector induces cytotoxicity in canine breast tumor cells under hypoxia.Veterinary research communications · 2016Article
- Advanced new strategies for metastatic cancer treatment by therapeutic stem cells and oncolytic virotherapy.Oncotarget · 2016Review
- Article
- The effect of heterogeneous Transcription Start Sites (TSS) on the translatome: implications for the mammalian cellular phenotype.BMC genomics · 2015Article
- Detecting cancers through tumor-activatable minicircles that lead to a detectable blood biomarker.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Molecular-genetic imaging of cancer.Advances in cancer research · 2014Review
- Therapeutic anti-tumor effect of exogenous apoptin driven by human survivin gene promoter in a lentiviral construct.Archives of medical science : AMS · 2013Article
- Potent, tumor-specific gene expression in an orthotopic hepatoma rat model using a Survivin-targeted, amplifiable adenoviral vector.Gene therapy · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 3 countries.
Funding
Abstract
Gene therapy is a novel therapy for melanoma. To date, however, there is still no powerful tumor specific promoter (TSP) to restrict the transgene expression in melanoma cells. In order to define a useful TSP for targeting in the context of melanoma gene therapy, four promoters, the cyclooxygenase-2 (Cox-2), alpha-chemokine SDF-1 receptor (CXCR4), epithelial glycoprotein 2 (EGP-2), and survivin, were tested in both established melanoma cell lines and primary melanoma cells. We employed recombinant adenoviral vectors (reAds) each with a candidate TSP (the Cox-2, CXCR4, EGP-2, or survivin), a reporter luciferase gene, and a poly-A signal, all of which were inserted into the E1-deleted region. A reAdGL3Bcytomegalovirus (CMV), containing the CMV promoter and luciferase gene, was used as a positive control to normalize the luciferase activity. Luciferase activity was measured in multiple tumor cell lines and two primary melanoma cell cultures after infection with reAds. Human epithelial melanocytes, HEM, were used as normal control. In contrast to three other promoters, the survivin promoter exhibited the highest activities within both melanoma cell lines and primary melanoma cells, but not in HEMs. Additionally, the survivin promoter exhibited very low activities in major mouse organs including the liver, in vivo. EGP-2 is not active in melanoma; messenger RNA expressions were correlated to promoter activities both in melanoma cell lines and primary cell cultures. Thus, these data suggest that the survivin promoter achieved a 'tumor-on/liver-off' profile, and thus represents a potentially useful tumor-specific promoter with applications for transcriptional targeting of Ad vector-based cancer gene therapy or oncolysis to melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.